We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HbA1c Point-of-Care Test Reliably Diagnoses Diabetes

By LabMedica International staff writers
Posted on 11 Apr 2019
Print article
Image: The AfinionHbA1c assay cartridge is used to test for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, which is used to monitor metabolic control in patients with diabetes (Photo courtesy of Alere).
Image: The AfinionHbA1c assay cartridge is used to test for quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, which is used to monitor metabolic control in patients with diabetes (Photo courtesy of Alere).
Glycated hemoglobin is a form of hemoglobin that is covalently bound to glucose. It is formed in a non-enzymatic glycation pathway by hemoglobin's exposure to plasma glucose.

By measuring glycated hemoglobin (HbA1c), clinicians are able to get an overall picture of what the average blood sugar levels have been over a period of weeks/months. Point-of-care (POC) hemoglobin A1c (HbA1c) testing has advantages over laboratory testing, but some questions have remained regarding the accuracy and precision of these methods.

Scientists collaborating with Abbott Rapid Diagnostics (San Diego, CA, USA) carried out a prospective and observational study using samples from 120 adults (mean age, 57 years; 56% women) across a range of HbA1c levels (4%-15%) that were taken by finger stick at three clinical sites in the USA. Four groups were formed based on HbA1c levels and categorized as low (4%-5.99%), threshold (6%-6.99%), medium (7%-9.99%) and high (more than 10%).

Venous blood samples were also taken from each participant, and three from each HbA1c group were analyzed using a POC test. The POC test assessed in the study was the Afinion HbA1c Dx test (Alere Technologies, Waltham, MA, USA). The precision of the POC test using venous blood was evaluated from samples run in four replicates on each of three test cartridge lots, twice per day for 10 consecutive days. The SD and CV by study site and overall were calculated.

The investigators found that using the point-of-care test with finger-stick and venous blood samples was “highly correlated” with the National Glycohemoglobin Standardization Program (NGSP) values. They also noted small bias results when comparing point-of-care testing by finger-stick testing (mean differential bias, –0.021%) and venous blood samples (mean differential bias, –0.005%). In addition, 97.5% of results from the finger-stick point-of-care tests and 97.1% of the venous blood point-of-care tests fell within 6% of the reference method from the Diabetes Control and Complications Trial. At least 92.5% of results are currently required to fall within this range by the NGSP, although the program will adjust the requirements to be 90% within 5% of the reference result this year. They noted that 95% of the finger-stick point-of-care test results and 93.3% of the venous blood POC test results fell within 5% of the reference in these new requirements.

The authors concluded that point-of-care HbA1c testing has the potential to expand patient access to diabetes diagnostic testing and expedite medical decisions and interventions aimed at the prevention of diabetes and its complications, particularly for those who face challenges in accessing traditional health care settings or attending multiple laboratory and physician follow-up appointments. The study was published on March 10, 2019, in the Journal of Diabetes Science and Technology.

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Uric Acid and Blood Glucose Meter
URIT-10

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.